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GeneXpert TB 8: A point-of-care 
diagnostic pilot
To the Editor: The point-of-care (POC) GeneXpert MTB/RIF detects 
Mycobacterium tuberculosis (MTB) and drug resistance in under 2 
hours and was hailed a ‘game-changer’ for tuberculosis (TB) control.[1] 
Recent results from Evaluating a New Diagnostic Trial (EXTEND) 
show that while implementing the GeneXpert had more confirmations 
of TB than sputum microscopy, levels of loss to follow-up and 
mortality were not reduced in the GeneXpert group.[2] These results are 
discouraging. However, GeneXpert was not used as a true POC service. 
Using the diagnostic at POC, where results are handed to patients at 
the time and place of sample collection, may yield different outcomes.
The Desmond Tutu HIV Foundation has piloted the GeneXpert 
in the Tutu Tester Mobile Clinic operating on the Cape Flats in Cape 
Town, Western Cape Province, South Africa.
The context. The Western Cape has one of the highest incidence 
rates of TB in the world.[3] The uncontrolled spread of TB has led to its 
being declared a national emergency.[4] Accessible healthcare promotes 
health-seeking and enables patients to become more active in their own 
healthcare.[5] Limited access means that treatable diseases such as HIV 
and TB go undiagnosed,[6] and many enter care with advanced disease. 
Providing POC testing can facilitate entry into the HIV/TB treatment 
cascade[7] for many in the Cape Town metropole. To facilitate treatment 
access further, the Foundation has piloted the GeneXpert in under-
resourced communities with a high burden of disease.
Intervention. Implementing the GeneXpert in the mobile clinic has 
shortened the diagnostic period. Patient samples can be analysed for 
TB DNA and the results can be handed back within 2 hours.[8] Most 
clients leave with their test result and a referral letter to their nearest 
clinic. This allows for fast-tracking for medication prescrip tions. 
Through active case finding, mobile clinics reach people who often do 
not access healthcare and patients are therefore infectious for shorter 
periods, helping to combat TB transmission. In addition, people who 
could not wait 2 hours for TB results were followed up telephonically 
and linkage to care was facilitated with the relevant clinic.
Data to date. In a 3-month period, 66 tests were conducted with 
HIV-positive clients with low CD4+ counts and clients with World 
Health Organization TB symptoms. Of these, nine (13.6%) tested 
positive for MTB. Rifampicin resistance was found in two (22.2%) 
of nine TB-positive clients (3.0% of 66 tested). Of the nine clients, 
seven were linked into care within 48 hours (one client linked into 
care 10 days after testing). All these clients received their first dose of 
medication on the day of linking to a healthcare facility.
Conclusion. These very preliminary data indicate that the Gene-
Xpert can be used at the point of patient contact, and when doing 
so, therapy can be initiated on the same day or very soon thereafter.
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